Araştırma Makalesi

Paraoxonase Gene Polymorphism Analysis in Pediatric Diabetic Patients

Cilt: 52 Sayı: 3 16 Eylül 2025
PDF İndir
EN TR

Paraoxonase Gene Polymorphism Analysis in Pediatric Diabetic Patients

Öz

Objective: Identifying gene polymorphisms linked to childhood-onset diabetes mellitus (DM), a multifactorial disease, will illuminate its genetic underpinnings. This study aimed to explore the association between childhood DM and the polymorphisms Paraoxonase1 (PON1) 55 and PON1 192. Method: A total of 129 children who applied to our Child Health and Diseases Endocrinology outpatient clinic participated in this prospective research. The study included 75 children with diabetes, aged 3–15 years (Patient Group-PG), and 54 healthy children (Control Group-CG) as a control. Genotyping of PON1 55 and PON1 192 polymorphisms was performed in study patients using Polymerase Chain Reaction (PCR) and RFLP methods following DNA isolation. Results: Of 54 CG, 21 (38.9%) displayed the homozygous normal (LL) PON1 55 genotypes. The PG contained 25 (33.3%) homozygous normal patients out of 75. In the CG, 25 participants (46.3%) and 39 participants in the PG (52.0%) had the heterozygous (LM) genotype. The homozygous mutant (MM) genotype was observed in 8 (14.8%) of CG and 11 (14.7%) of PG. The CG showed 67 L alleles, representing 62.0% of the total alleles. On the other hand, the number was 89 (59.3%) in the PG. The two groups showed no statistically significant differences in gene polymorphisms, allele frequencies, and M and R allele distribution. Conclusion: No significant relationship was observed between PON1 55 and PON1 192 gene polymorphisms and DM in our study.

Anahtar Kelimeler

Etik Beyan

All procedures were conducted in accordance with institutional and national ethical standards, and the 2008 Helsinki Declaration revision. The ethics committee (Approval No. 334, 05.08.2014) approved our study, and we obtained informed consent from all participants’ legal representatives.

Kaynakça

  1. 1.Adiga U, Banawalikar N and Menambath DT.Association of paraoxonase 1 activity and insulinresistance models in type 2 diabetes mellitus: Cross-sectional study. J Chin Med Assoc 2022;85:77-80.
  2. 2.Besser REJ, Bell KJ, Couper JJ, et al. ISPAD ClinicalPractice Consensus Guidelines 2022: Stages of type1 diabetes in children and adolescents. PediatrDiabetes 2022;23:1175-87.
  3. 3.Dada AO, Ikpegbu UA, Okunowo LO, et al. Plasmaparaoxonase-1 activity levels in patients with type 2diabetes mellitus in Lagos State University TeachingHospital, Lagos, Southwest Nigeria: a cross-sectionalstudy. Pan Afr Med J 2023;45:40.
  4. 4.El-Lebedy D, Kafoury M, Abd-El Haleem D, et al.Paraoxonase-1 gene Q192R and L55Mpolymorphisms and risk of cardiovascular disease in Egyptian patients with type 2 diabetes mellitus. J Diabetes Metab Disord 2014;13:124.
  5. 5. Helaly MAH, Abdel-Khalek EES, Abdel-Hafez HA, et al. Paraoxonase1 55 and 192 gene polymorphisms in an Egyptian population with diabetic complications.Int J Diabetes Dev Ctries 2013;33:207-12.
  6. 6.Grzegorzewska AE, Ostromecka K, Adamska P, etal. Paraoxonase 1 gene polymorphisms concerningnon-insulin-dependent diabetes mellitusnephropathy in hemodialysis patients. J DiabetesComplications 2020;34:107687.
  7. 7.Sanda GM, Toma L, Barbalata T, et al. Clusterin,paraoxonase 1, and myeloperoxidase alterationsinduce high-density lipoproteins dysfunction andcontribute to peripheral artery disease; aggravationby type 2 diabetes mellitus. Biofactors 2022;48:454-68.
  8. 8. Nawaka N, Pansang P, Saniwa A, et al. Paraoxonase1 (PON1) L55M and Q192R polymorphisms are notassociated with chronic kidney disease in Thaiindividuals with type 2 diabetes. Int J Clin Pract2021;75:e1498.

Ayrıntılar

Birincil Dil

İngilizce

Konular

Sağlık Kurumları Yönetimi, Tıp Eğitimi, Sağlık Hizmetleri ve Sistemleri (Diğer)

Bölüm

Araştırma Makalesi

Yazarlar

Pınar Kanlıoğlu * Bu kişi benim
Türkiye

Yusuf Kenan Haspolat Bu kişi benim
Türkiye

Yayımlanma Tarihi

16 Eylül 2025

Gönderilme Tarihi

24 Temmuz 2025

Kabul Tarihi

4 Ağustos 2025

Yayımlandığı Sayı

Yıl 2025 Cilt: 52 Sayı: 3

Kaynak Göster

APA
Kanlıoğlu, P., Tekeş, S., Yıldırım, R., Oral, D., & Haspolat, Y. K. (2025). Paraoxonase Gene Polymorphism Analysis in Pediatric Diabetic Patients. Dicle Medical Journal, 52(3), 535-542. https://doi.org/10.5798/dicletip.1785093
AMA
1.Kanlıoğlu P, Tekeş S, Yıldırım R, Oral D, Haspolat YK. Paraoxonase Gene Polymorphism Analysis in Pediatric Diabetic Patients. diclemedj. 2025;52(3):535-542. doi:10.5798/dicletip.1785093
Chicago
Kanlıoğlu, Pınar, Selahattin Tekeş, Ruken Yıldırım, Diclehan Oral, ve Yusuf Kenan Haspolat. 2025. “Paraoxonase Gene Polymorphism Analysis in Pediatric Diabetic Patients”. Dicle Medical Journal 52 (3): 535-42. https://doi.org/10.5798/dicletip.1785093.
EndNote
Kanlıoğlu P, Tekeş S, Yıldırım R, Oral D, Haspolat YK (01 Eylül 2025) Paraoxonase Gene Polymorphism Analysis in Pediatric Diabetic Patients. Dicle Medical Journal 52 3 535–542.
IEEE
[1]P. Kanlıoğlu, S. Tekeş, R. Yıldırım, D. Oral, ve Y. K. Haspolat, “Paraoxonase Gene Polymorphism Analysis in Pediatric Diabetic Patients”, diclemedj, c. 52, sy 3, ss. 535–542, Eyl. 2025, doi: 10.5798/dicletip.1785093.
ISNAD
Kanlıoğlu, Pınar - Tekeş, Selahattin - Yıldırım, Ruken - Oral, Diclehan - Haspolat, Yusuf Kenan. “Paraoxonase Gene Polymorphism Analysis in Pediatric Diabetic Patients”. Dicle Medical Journal 52/3 (01 Eylül 2025): 535-542. https://doi.org/10.5798/dicletip.1785093.
JAMA
1.Kanlıoğlu P, Tekeş S, Yıldırım R, Oral D, Haspolat YK. Paraoxonase Gene Polymorphism Analysis in Pediatric Diabetic Patients. diclemedj. 2025;52:535–542.
MLA
Kanlıoğlu, Pınar, vd. “Paraoxonase Gene Polymorphism Analysis in Pediatric Diabetic Patients”. Dicle Medical Journal, c. 52, sy 3, Eylül 2025, ss. 535-42, doi:10.5798/dicletip.1785093.
Vancouver
1.Pınar Kanlıoğlu, Selahattin Tekeş, Ruken Yıldırım, Diclehan Oral, Yusuf Kenan Haspolat. Paraoxonase Gene Polymorphism Analysis in Pediatric Diabetic Patients. diclemedj. 01 Eylül 2025;52(3):535-42. doi:10.5798/dicletip.1785093